Estimates Revisions Rapport Therapeutics, Inc.
Stocks
RAPP
US75383L1026
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
19:45:03 20/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 47.46 USD | -3.29% |
|
+0.96% | +57.60% |
| 08-05 | Rapport Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 07-28 | William Blair Initiates Rapport Therapeutics at Outperform | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | |||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- RAPP Stock
- Consensus Rapport Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
